NCT00992745View on ClinicalTrials.gov

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Prostate Cancer
Interventions
DRUG

123-I-MIP-1072

Single 10 mCi intravenous injection

DRUG

111-In capromab pendetide

Single 5 mCi intravenous injection

DRUG

123-I-MIP-1072

Single 5 mCi intravenous injection

Trial Locations (7)

10065

New York Presbyterian Hospital - Weill Cornell Medical College, New York

21201

University of Maryland, Baltimore

27710

Duke University Medical Center, Durham

77030

Vanguard Urologic Research Foundation, Houston

92663

Pacific Coast Imaging, Newport Beach

92677

West Coast Radiology Centers, Laguna Niguel

94143

University of California - San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Molecular Insight Pharmaceuticals, Inc.

INDUSTRY